Form 4: Addex Therapeutics Executive Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Mikhail Kalinichev, HEAD OF TRANSLATIONAL SCIENCE of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Summary

  • Disposition to the issuer: disposed of 306,765 Common Stock on September 2, 2026 (Direct).
  • Grant/award: acquired 306,765 Common Stock on September 2, 2026; holds 306,765 after (Direct).
  • Disposition to the issuer: disposed of 200,000 Stock-option (Right to Buy) on September 2, 2026 (Direct).
  • Grant/award: acquired 200,000 Stock-option (Right to Buy) on September 2, 2026; holds 200,000 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Mikhail Kalinichev — Officer (HEAD OF TRANSLATIONAL SCIENCE)

DateTransactionSecuritySharesPriceValueHeld After
2026-09-02Disposition to the issuerCommon Stock306,765——0
2026-09-02Grant/awardCommon Stock306,765——306,765
2026-09-02Disposition to the issuerStock-option (Right to Buy)200,000——0
2026-09-02Grant/awardStock-option (Right to Buy)200,000——200,000

Key Dates

DateDescription
2026-09-02Disposition to the issuer (306,765 shares)
2026-09-02Grant/award (306,765 shares)
2026-09-02Disposition to the issuer (200,000 shares)
2026-09-02Grant/award (200,000 shares)

Keywords

insider transaction, Form 4, ADXN, Addex Therapeutics Ltd., neutral, Mikhail Kalinichev

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.